Sygnature
SYGNATURE_DISCOVERY_TM_logo_NAVY-BLUE_RGB
BLUE
SYGNATURE_DISCOVERY_TM_logo_WHITE_RGB
WHITE
Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
    Cover graphic for the DHX9 inhibitor case study showing the title From Lead to Pre Candidate Nomination in 18 Months with STORM Therapeutics and Sygnature Discovery branding.

    STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months

    Case study
Want to find out more about Drug Discovery and our services?
Find out more
  • Scientific Solutions Overview
  • Computer Aided Drug Design

    Computer Aided Drug Design

    Overview
  • Bioinformatics

    Bioinformatics

  • Target Analysis

    Target Analysis

  • Virtual Screening

    Virtual Screening

  • Structure Based Drug Design

    Structure Based Drug Design

  • Generative AI and Machine Learning

    Generative AI and Machine Learning

  • Ligand Based Drug Design

    Ligand Based Drug Design

  • Library Design

    Library Design

  • ADMET Predictions

    ADMET Predictions

  • Informatics

    Informatics

Featured Resources

  • Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
    |

    Rapid creation of ideas using generative AI (GenAI) with Iktos Makya

    Case study
  • Protein Science and Structural Biology

    Protein Science and Structural Biology

    Overview
  • Protein Expression and Purification

    Protein Expression and Purification

  • Membrane Proteins

    Membrane Proteins

  • Antibodies and Biotherapeutics

    Antibodies and Biotherapeutics

  • Structural Biology

    Structural Biology

  • X-Ray Crystallography

    X-Ray Crystallography

  • cryo-EM

    cryo-EM

  • Macromolecular NMR

    Macromolecular NMR

  • Protein Characterization

    Protein Characterization

  • Protein Mass Spectrometry

    Protein Mass Spectrometry

  • FIDA

    FIDA

Featured Resources

  • A Comparison of the Structural Techniques used at Sygnature Discovery: X-ray Crystallography, NMR and Cryo-EM
    A Comparison of the Structural Techniques used at Sygnature Discovery: X-ray Crystallography, NMR and Cryo-EM

    A Comparison of the Structural Techniques used at Sygnature Discovery: X-ray Crystallography, NMR and Cryo-EM

    Blog
  • Bioscience

    Bioscience

    Overview
  • Cell Line Generation

    Cell Line Generation

  • Assay Development

    Assay Development

  • Electrophysiology

    Electrophysiology

  • High Throughput Screening

    High Throughput Screening

  • Cell Based Assays

    Cell Based Assays

  • Biochemical Assays

    Biochemical Assays

  • Biophysical Assays

    Biophysical Assays

  • Primary Cells and Tissues

    Primary Cells and Tissues

  • Integrating Hit Finding and Direct-to-Biology to Shorten Time to Development Candidate
    Preview of Sygnature Discovery poster illustrating Hit Synergy

    Integrating Hit Finding and Direct-to-Biology to Shorten Time to Development Candidate

    Poster
  • Chemistry

    Chemistry

    Overview
  • Medicinal Chemistry

    Medicinal Chemistry

  • Synthetic Chemistry

    Synthetic Chemistry

  • Process & Scale-up Chemistry

    Process & Scale-up Chemistry

  • NMR-Spectroscopy

    NMR-Spectroscopy

  • Separation Sciences

    Separation Sciences

  • High Throughput Chemistry

    High Throughput Chemistry

  • Why Early Process Chemistry Matters?

    Why Early Process Chemistry Matters?

    Poster
  • Drug Metabolism and Pharmacokinetics

    Drug Metabolism and Pharmacokinetics

    Overview
  • Physicochemical Profiling

    Physicochemical Profiling

  • Chemical & Metabolic Stability

    Chemical & Metabolic Stability

  • Permeability

    Permeability

  • Tissue Binding

    Tissue Binding

  • Drug-Drug Interactions

    Drug-Drug Interactions

  • Biotransformation

    Biotransformation

  • Analytical Method Development & Bioanalysis

    Analytical Method Development & Bioanalysis

  • in vivo Pharmacokinetic & Pharmacodynamic Studies

    in vivo Pharmacokinetic & Pharmacodynamic Studies

  • PK & PK/PD Modelling and Simulation

    PK & PK/PD Modelling and Simulation

  • DMPK Consultancy

    DMPK Consultancy

  • Dedicated DMPK for Bifunctional Degraders: A Flexible Approach for Flexible Molecules
    Sygnature Discovery poster highlighting DMPK approaches for bifunctional degraders and key assay considerations.

    Dedicated DMPK for Bifunctional Degraders: A Flexible Approach for Flexible Molecules

    Poster

in vivo Pharmacology solutions

  • in vivo Pharmacology

    in vivo Pharmacology

    Overview
  • CNS/Pain Models

    CNS/Pain Models

  • Metabolic Disease Models

    Metabolic Disease Models

  • Inflammation & Immunology Models

    Inflammation & Immunology Models

  • Oncology Models

    Oncology Models

  • Non-Regulatory Toxicology

    Non-Regulatory Toxicology

  • in vivo Pharmacokinetics

    in vivo Pharmacokinetics

  • ex vivo Tissue Analysis

    ex vivo Tissue Analysis

  • SfN 2025 - Evaluation of Two Novel Compounds Compared to Methadone on Morphine Withdrawal in a Rat Model of Physical dependence

    SfN 2025 - Evaluation of Two Novel Compounds Compared to Methadone on Morphine Withdrawal in a Rat Model of Physical dependence

    Poster
  • Form & Formulation

    Form & Formulation

    Overview
  • Early Clinical Formulation

    Early Clinical Formulation

  • Solid Form Analysis

    Solid Form Analysis

  • Salt and Co-Crystal Screening

    Salt and Co-Crystal Screening

  • Polymorph Screening

    Polymorph Screening

  • Pre-Clinical Formulation

    Pre-Clinical Formulation

  • Assessing Lypoprotectant Effect on Particle Size of Liposomal Systems
    Discover how Sygnature Discovery’s form and formulation experts optimise freeze-dried liposomal formulations to maintain particle size and stability.

    Assessing Lypoprotectant Effect on Particle Size of Liposomal Systems

    Poster
Want to find out more about our Scientific Solutions?
Find out more
  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Next-Generation Antibody Drug Conjugates

    Next-Generation Antibody Drug Conjugates

    E book
Want to find out more about Modalities?
Find out more
  • Target Classes Overview
    Comprehensive target class solutions integrate advanced assays, structural biology, and medicinal chemistry to accelerate hit-to-lead and candidate selection.
  • GPCRs
    End-to-end GPCR expertise combines advanced assays and structural biology to accelerate candidate selection and deliver confident, data-driven decisions.
  • Transporters
    Advanced transporter assays and electrophysiology deliver robust, high-throughput data for hit identification, validation, and lead optimization in drug discovery.

Ion channels Ion channels

  • Ion Channels

    Ion Channels

    Overview
  • GABAA Receptors

    GABAA Receptors

  • NMDA Receptors

    NMDA Receptors

  • Glycine Receptors

    Glycine Receptors

  • Nicotinic Receptors

    Nicotinic Receptors

  • TRP Channels

    TRP Channels

  • Sodium Channels

    Sodium Channels

  • Calcium Channels

    Calcium Channels

  • Potassium Channels

    Potassium Channels

  • Chloride Channels

    Chloride Channels

  • TMEM175

    TMEM175

Featured Resources

  • Delivering Custom Cell-Based Tools for Drug Discovery
    cover for eBook exploring Sygnature Discovery's cell line generation capabilities and target class applications for ion channel, GPCR and transporter drug discovery

    Delivering Custom Cell-Based Tools for Drug Discovery

    E book

Featured Resources Overview

  • Sygnature Discovery Successfully Provides Clinical Candidate to Corcept Therapeutics
    Sygnature Drug Discovery - Post

    Sygnature Discovery Successfully Provides Clinical Candidate to Corcept Therapeutics

    News

    July 30, 2015

Featured Resources

  • Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities

    Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities

    News Bioscience Optional Target classes

    January 17, 2023

Want to find out more about Target classes?
Find out more
  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477
    Primary Tissues of body|CCS1477 retains activity in a BETi resistant 22Rv1 cell-line|CellCentric thank you note|10.1.2 Graphs

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
Want to find out more about Therapeutic Areas?
Find out more

Categories View all

  • Blog

    Blog

  • Webinars & Podcasts

    Webinars & Podcasts

  • Posters

    Posters

  • Journal Papers

    Journal Papers

  • Technical Notes

    Technical Notes

  • Case Studies

    Case Studies

  • eBooks

    eBooks

  • Protocols

    Protocols

Featured Resources

  • News

    News

    Stay up to date with the latest company updates, milestones, and announcements.

  • Events

    Events

    Explore upcoming conferences and scientific meetings where you can connect with our team.

Have a question or need to get in touch with us?
Find out more
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers
    Explore careers at Sygnature Discovery. Join a global team delivering exceptional outcomes through collaboration, innovation, and integrity.

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Have a question or need to get in touch with us?
Contact us
Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
    Cover graphic for the DHX9 inhibitor case study showing the title From Lead to Pre Candidate Nomination in 18 Months with STORM Therapeutics and Sygnature Discovery branding.

    STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months

    Case study
  • Scientific Solutions Overview
    • Computer Aided Drug Design Overview
    • Bioinformatics
    • Target Analysis
    • Virtual Screening
    • Structure Based Drug Design
    • Generative AI and Machine Learning
    • Ligand Based Drug Design
    • Library Design
    • ADMET Predictions
    • Informatics

    Featured Resources

    • |
      Case study
      Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
    • Protein Science and Structural Biology Overview
    • Protein Expression and Purification
    • Membrane Proteins
    • Antibodies and Biotherapeutics
    • Structural Biology
    • X-Ray Crystallography
    • cryo-EM
    • Macromolecular NMR
    • Protein Characterization
    • Protein Mass Spectrometry
    • FIDA

    Featured Resources

    • A Comparison of the Structural Techniques used at Sygnature Discovery: X-ray Crystallography, NMR and Cryo-EM
      Blog
      A Comparison of the Structural Techniques used at Sygnature Discovery: X-ray Crystallography, NMR and Cryo-EM
    • Bioscience Overview
    • Cell Line Generation
    • Assay Development
    • Electrophysiology
    • High Throughput Screening
    • Cell Based Assays
    • Biochemical Assays
    • Biophysical Assays
    • Primary Cells and Tissues
    • Preview of Sygnature Discovery poster illustrating Hit Synergy
      Poster
      Integrating Hit Finding and Direct-to-Biology to Shorten Time to Development Candidate
    • Chemistry Overview
    • Medicinal Chemistry
    • Synthetic Chemistry
    • Process & Scale-up Chemistry
    • NMR-Spectroscopy
    • Separation Sciences
    • High Throughput Chemistry
    • Poster
      Why Early Process Chemistry Matters?
    • Drug Metabolism and Pharmacokinetics Overview
    • Physicochemical Profiling
    • Chemical & Metabolic Stability
    • Permeability
    • Tissue Binding
    • Drug-Drug Interactions
    • Biotransformation
    • Analytical Method Development & Bioanalysis
    • in vivo Pharmacokinetic & Pharmacodynamic Studies
    • PK & PK/PD Modelling and Simulation
    • DMPK Consultancy
    • Sygnature Discovery poster highlighting DMPK approaches for bifunctional degraders and key assay considerations.
      Poster
      Dedicated DMPK for Bifunctional Degraders: A Flexible Approach for Flexible Molecules
  • in vivo Pharmacology solutions

    • in vivo Pharmacology Overview
    • CNS/Pain Models
    • Metabolic Disease Models
    • Inflammation & Immunology Models
    • Oncology Models
    • Non-Regulatory Toxicology
    • in vivo Pharmacokinetics
    • ex vivo Tissue Analysis
    • Poster
      SfN 2025 - Evaluation of Two Novel Compounds Compared to Methadone on Morphine Withdrawal in a Rat Model of Physical dependence
    • Form & Formulation Overview
    • Early Clinical Formulation
    • Solid Form Analysis
    • Salt and Co-Crystal Screening
    • Polymorph Screening
    • Pre-Clinical Formulation
    • Discover how Sygnature Discovery’s form and formulation experts optimise freeze-dried liposomal formulations to maintain particle size and stability.
      Poster
      Assessing Lypoprotectant Effect on Particle Size of Liposomal Systems
  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Next-Generation Antibody Drug Conjugates

    Next-Generation Antibody Drug Conjugates

    E book
  • Target Classes Overview
    Comprehensive target class solutions integrate advanced assays, structural biology, and medicinal chemistry to accelerate hit-to-lead and candidate selection.
  • Ion channels Ion channels

    • Ion Channels Overview
    • GABAA Receptors
    • NMDA Receptors
    • Glycine Receptors
    • Nicotinic Receptors
    • TRP Channels
    • Sodium Channels
    • Calcium Channels
    • Potassium Channels
    • Chloride Channels
    • TMEM175

    Featured Resources

    • cover for eBook exploring Sygnature Discovery's cell line generation capabilities and target class applications for ion channel, GPCR and transporter drug discovery
      E book
      Delivering Custom Cell-Based Tools for Drug Discovery
  • GPCRs
    End-to-end GPCR expertise combines advanced assays and structural biology to accelerate candidate selection and deliver confident, data-driven decisions.
  • Transporters
    Advanced transporter assays and electrophysiology deliver robust, high-throughput data for hit identification, validation, and lead optimization in drug discovery.
  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477
    Primary Tissues of body|CCS1477 retains activity in a BETi resistant 22Rv1 cell-line|CellCentric thank you note|10.1.2 Graphs

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • Categories View all

    • Blog
    • Webinars & Podcasts
    • Posters
    • Journal Papers
    • Technical Notes
    • Case Studies
    • eBooks
    • Protocols

    Featured Resources

    • News
      Stay up to date with the latest company updates, milestones, and announcements.
    • Events
      Explore upcoming conferences and scientific meetings where you can connect with our team.
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers
    Explore careers at Sygnature Discovery. Join a global team delivering exceptional outcomes through collaboration, innovation, and integrity.

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Background

Ready to start a conversation?

Sygnature Discovery provides drug discovery phase solutions, globally. Contact our team today to find out how we can support your journey to the clinic.

Get in touch
Our Office Locations

Headquarters

UK (Nottingham)

BioCity, Pennyfoot Street
Nottingham NG1 1GR

View all locations

01159415401

[email protected]

[email protected]

Drug Discovery

Integrated Drug Discovery

Target Identification & Validation

Hit Identification

Hit-to-Lead

Lead Optimization

modalities

Small Molecules

Peptides

Targeted Protein Degradation

ADCs

Biologics

Target Classes

Ion channels

GPCRs

Transporters

Scientific solutions

Computer Aided Drug Design

Protein & Structure

Bioscience

Chemistry

Drug Metabolism and Pharmacokinetics (DMPK)

in vivo Pharmacology

Form & Formulation

Therapeutic Areas

Oncology

Inflammation and Immunology

Neuroscience

Metabolic Diseases

Website

About Us

Meet our Team

Working with us

Contact

Careers

Environment, social, governance

Resource Hub

Blog

Webinars & Podcasts

Posters

Journal Papers

Technical Notes

eBooks

Protocols

Case Studies

News

Events

Copied to clipboard

Privacy Policy

Cookie Policy

Website terms of use

Modern Slavery Statement

Copyright 2026 Sygnature

This website is operated by Sygnature Discovery Limited, a company registered in England and Wales under Company Number 05210563, with its registered office at The Discovery Building, BioCity, Pennyfoot Street, Nottingham, Nottinghamshire, United Kingdom, NG1 1GR, and NuChem Sciences Inc., NEQ 1178967270, with its registered address at 201-2350 Rue Cohen, Montréal, Québec, H4R 2N6, Canada

An error has occurred, please try again later.An error has occurred, please try again later.

You're in the right place!

Peak Proteins has now fully integrated with Sygnature Discovery.